Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).
Authors
Jaclyn P. Lyman
Parker Institute for Cancer Immunotherapy, San Francisco, CA;
Jaclyn P. Lyman , Christopher R Cabanski , Stephen Maddock , Robert A. Wolff , Zev A. Wainberg , Andrew H. Ko , Osama E. Rahma , George A. Fisher Jr., Peter Edward Gabriel , Abigail Doucette , Binbin Zheng-Lin , Molly A. Maloy , Ute Dugan , Justin P. Fairchild , Marko Spasic , Jill O'Donnell-Tormey , Robert H. Vonderheide , Mark H. O'Hara , Eileen Mary O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
Clinical Trial Registration Number
NCT03214250
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 757)
DOI
10.1200/JCO.2023.41.4_suppl.757
Abstract #
757
Poster Bd #
N4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (Sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.
First Author: Mark H. O'Hara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Ru Jia
Poster
2023 ASCO Annual Meeting
A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Guang-Hai Dai
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.
First Author: Jaclyn Paige Lyman